PKX 001

Drug Profile

PKX 001

Alternative Names: PKX-001

Latest Information Update: 31 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Institut National des Sciences Appliquees de Rouen; ProtoKinetix
  • Developer ProtoKinetix; University of Alberta
  • Class Glycopeptides; Glycoproteins; Small molecules
  • Mechanism of Action Antioxidants; Free radical scavengers; Selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Type 1 diabetes mellitus

Most Recent Events

  • 16 Feb 2017 Phase-I/II clinical trials in Type-1 diabetes mellitus in Canada (unspecified route) (NCT03073577)
  • 17 Jan 2017 University of Alberta submits Investigational Testing Authorization (ITA) to Health Canada for Type-1 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top